Evidence map›Paper›PMID 40213600›Full record

ArticleAdvanced biomedical research2025

The

Roghayeh Farajnabi, Zahra Hojjati Bonab, Neda Shagayegh

Abstract read
In one paragraph

Article in Advanced biomedical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Roghayeh FarajnabiDepartment of Microbiology, Bonab Branch, Islamic Azad University, Bonab, Iran.
Zahra Hojjati BonabDepartment of Microbiology, Bonab Branch, Islamic Azad University, Bonab, Iran.
Neda ShagayeghDepartment of Biology, Faculty of Basic Sciences, Razi University, Kermanshah, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Helicobacter pylori is a Gram negative bacterium in the human stomach. Considering the side effects of the drug regimen and the prevalence of antibiotic resistance, in this project, the antimicrobial effect of aloe vera extracts on Helicobacter pylori was tested. Materials and Methods: Evaluation of the antimicrobial effect of aloe vera extract on Helicobacter pylori was done using diffusion methods in agar, and the diameter of the nongrowth halo was measured. The molecular interaction between the active ingredients of aloe vera and urease enzyme was investigated with Mulgroo Virtual Docker (MVD) software. Results: The diameter of the halo of no growth at a concentration of 1000 mg/ml in aloe vera was 19 mm, and the maximum diameter of no growth was observed in the ethanolic extract. Conclusion: According to our results, the ethanolic extract of aloe vera can be suggested as a good option as an antimicrobial supplement for Helicobacter pylori.

Indexed as

Aloe vera extractantimicrobialhelicobacter pylorimolecular docking

Identifiers

PMID40213600
PMCPMC11981037

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.